Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients
| Autor: | Balogh, Gabriela Andrea, Mailo, Daniel, Nardi, Héctor, Corte, María Marta, Vincent, Esteban, Barutta, Elena, Lizarraga, Guillermo, Lizarraga, Pablo, Montero, Héctor, Gentili, Roberto, Mordoh, Jose |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
P53 MUTATIONAL ANALYSIS
Cancer Research Biology medicine.disease_cause Serology purl.org/becyt/ford/1 [https] Ciencias Biológicas Breast cancer Immunology and Microbiology (miscellaneous) BREAST CANCER SEROLOGICAL DETECTION OF P53 MUTATIONS P53 MUTANTIONAL ANALYSIS medicine purl.org/becyt/ford/1.6 [https] Oncogene Cancer General Medicine Articles Bioquímica y Biología Molecular medicine.disease Cancer research Immunohistochemistry Breast disease Breast carcinoma Carcinogenesis CIENCIAS NATURALES Y EXACTAS |
| Zdroj: | CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET |
| Popis: | The aim of this study was to compare the sensitivity of the serological level of anti-p53 antibodies in breast cancer patients and to correlate its expression level with patient age, histological stage and grade of tumor differentiation. Total p53 protein expression (mutant and wild-type) was also determined in the breast cancer tissues using immunohistochemistry (IHCIHCIHC). The serological levels of mutant p53 expression were found to be age-dependent, reaching the highest level at 50 years of age. Faint or low detection was observed in patients ≤30 years of age. Anti-p53-antibodies were detected in patients ≤40 and ≥61 years of age. The serological levels of mutant p53 protein were highly detected in all stages of breast cancer, including the early stages. However, anti-p53 antibodies reached a high level of detection only in stage III III III III breast carcinomas. No expression was found in patients with benign breast disease. The detection of p53 mutations was dependent on the grade of tumor differentiation, achieving the highest level in the poorly differentiated breast carcinomas. Results from IHCIHCIHC were highly correlated with serological p53 mutational analysis. Our findings indicate that mutant p53 in serum is a promising novel parameter for the evaluation of cellular biology and the prognosis of breast cancer from its early stages using blood samples. Anti-p53 antibodies were demonstrated to be less sensitive in this study. It is also possible to use the expression of mutant p53 protein as a molecular marker to differentiate benign breast disease from breast carcinoma prior to surgery. Fil: Balogh, Gabriela Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Centro de Recursos Naturales Renovables de la Zona Semiarida. Universidad Nacional del Sur. Centro de Recursos Naturales Renovables de la Zona Semiarida; Argentina Fil: Mailo, Daniel. Fil: Nardi, Héctor. Hospital Interzonal Dr. José Penna. Departamento de Ginecología. Bahía Blanca; Argentina Fil: Corte, María Marta. Laboratorio de Patología. Bahía Blanca; Argentina Fil: Vincent, Esteban. Hospital de la Asociación Médica de Bahía Blanca. Departamento de Ginecología. Bahía Blanca; Argentina Fil: Barutta, Elena. Fil: Lizarraga, Guillermo. Fil: Lizarraga, Pablo. Fil: Montero, Héctor. Hospital Español. Departamento de Ginecología. Bahía Blanca; Argentina Fil: Gentili, Roberto. Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Pque. Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|